These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 1327264

  • 1. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
    Herbert JM, Laplace MC, Maffrand JP.
    J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
    [Abstract] [Full Text] [Related]

  • 2. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM, Bernat A, Valette G, Gigo V, Lale A, LaPlace MC, Lespy L, Savi P, Maffrand JP, Le Fur G.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [Abstract] [Full Text] [Related]

  • 3. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM, Fraisse L, Bachy A, Valette G, Savi P, Laplace MC, Lassalle J, Roche B, Lale A, Keane PE.
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [Abstract] [Full Text] [Related]

  • 4. In vitro inhibitory effect of SR 27417, a potent platelet-activating factor (PAF) receptor antagonist, on the PAF-induced bovine platelet aggregation.
    Bastos da Silva M, Delaunois A, Gustin P, Godeau JM, Lekeux P.
    Vet Res; 2000 Aug; 31(2):267-72. PubMed ID: 10779205
    [Abstract] [Full Text] [Related]

  • 5. Effect of SR 27417 on the binding of [3H]PAF to rabbit and human platelets and human polymorphonuclear leukocytes.
    Herbert JM, Laplace MC, Cailleau C, Maffrand JP.
    J Lipid Mediat; 1993 May; 7(1):57-78. PubMed ID: 8395255
    [Abstract] [Full Text] [Related]

  • 6. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
    Imanishi N, Murakami-Uchida M, Koike H, Natsume Y, Morooka S.
    Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
    [Abstract] [Full Text] [Related]

  • 7. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
    Ortega MP, García MC, Gijón MA, de Casa-Juana MF, Priego JG, Sanchez Crespo M, Sunkel C.
    J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
    Tsunoda H, Sakuma Y, Harada K, Muramoto K, Katayama S, Horie T, Shimomura N, Clark R, Miyazawa S, Okano K.
    Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
    [Abstract] [Full Text] [Related]

  • 9. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Szalkowski DM, MacIntyre DE, Bach TJ, Luell S, Meuer R, Sahoo SP, Alberts AW, Chabala JC.
    J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114
    [Abstract] [Full Text] [Related]

  • 10. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
    Crowley HJ, Yaremko B, Selig WM, Janero DR, Burghardt C, Welton AF, O'Donnell M.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
    [Abstract] [Full Text] [Related]

  • 11. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
    Tahraoui L, Floch A, Mondot S, Cavero I.
    Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
    Parry MJ, Alabaster VA, Cheeseman HE, Cooper K, deSouza RN, Keir RF.
    J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
    [Abstract] [Full Text] [Related]

  • 13. Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: binding and in vitro functional studies.
    Castro-Faria-Neto HC, Bozza PT, Cruz HN, Silva CL, Violante FA, Barbosa-Filho JM, Thomas G, Martins MA, Tibiriçá EV, Noel F.
    Planta Med; 1995 Apr; 61(2):101-5. PubMed ID: 7753913
    [Abstract] [Full Text] [Related]

  • 14. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
    Hwang SB, Lam MH, Alberts AW, Bugianesi RL, Chabala JC, Ponpipom MM.
    J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
    [Abstract] [Full Text] [Related]

  • 15. Inhibition by glaucocalyxin A of aggregation of rabbit platelets induced by ADP, arachidonic acid and platelet-activating factor, and inhibition of [3H]-PAF binding.
    Bin Z, Kun L.
    Thromb Haemost; 1992 Apr 02; 67(4):458-60. PubMed ID: 1631795
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
    Ring PC, Seldon PM, Barnes PJ, Giembycz MA.
    Mol Pharmacol; 1993 Feb 02; 43(2):302-12. PubMed ID: 8381515
    [Abstract] [Full Text] [Related]

  • 17. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J.
    J Pharmacol Exp Ther; 1997 Jan 02; 280(1):114-21. PubMed ID: 8996188
    [Abstract] [Full Text] [Related]

  • 18. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
    Floch A, Tahraoui L, Sedivy P, Cavero I.
    J Pharmacol Exp Ther; 1991 Aug 02; 258(2):567-75. PubMed ID: 1650834
    [Abstract] [Full Text] [Related]

  • 19. Functional validation of platelet-activating factor receptor sites characterized biochemically by a specific and reproducible [3H]platelet-activating factor binding in human platelets.
    Tahraoui L, Floch A, Cavero I.
    J Pharmacol Exp Ther; 1990 Mar 02; 252(3):1221-7. PubMed ID: 2156995
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
    Nagaoka J, Harada K, Kimura A, Kobayashi S, Murakami M, Yoshimura T, Yamada K, Asano O, Katayama K, Yamatsu I.
    Arzneimittelforschung; 1991 Jul 02; 41(7):719-24. PubMed ID: 1663352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.